Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
InVivium Capital is a venture capital fund based in Chicago, Illinois, focused on investments in the healthcare and life sciences sectors. Founded to provide significant value to patients, payers, providers, and the healthcare industry, the firm has established itself as a key player in the venture capital landscape. The firm primarily targets biotechnology and medical devices, aiming to identify innovations that can lead to substantial advancements in patient care.
The team at InVivium Capital consists of experienced professionals with backgrounds in healthcare and law, enabling them to navigate the complexities of the healthcare sector effectively. The firm operates from its headquarters at 400 N. Aberdeen St., Suite 900, Chicago, IL 60642, and has a commitment to supporting transformative solutions that enhance patient outcomes. Although specific fund sizes and assets under management (AUM) are not publicly disclosed, InVivium Capital is structured to provide follow-on capital through strategic partnerships.
InVivium Capital primarily invests in the biotechnology and medical devices sectors, with a clear emphasis on transformative healthcare innovations. The firm seeks opportunities that can lead to significant improvements in patient care and outcomes. Its investment strategy is centered on identifying innovations that provide 'step-change' value creation across the healthcare ecosystem, including patients, payers, providers, and pharma.
The firm primarily focuses on the United States but remains open to opportunistic investments in global and under-ventured regions. InVivium Capital engages in seed and growth-equity stages, allowing them to invest in early to mid-stage companies. The firm has the capacity to write checks that can increase significantly through co-investment partnerships, ensuring long-term capital continuity for its portfolio companies.
Michael Liang, Ph.D. - Managing Partner
Michael has 16 years of experience as a Partner at Baird Capital, focusing on healthcare investments. He previously worked as a healthcare investor at Advent Venture Partners and served as Director of R&D at Cortek, specializing in spinal orthopedics. He holds a BS in bioorganic chemistry from UC Berkeley and a PhD in biophysical chemistry from Stanford, along with a postdoctoral fellowship at Harvard.
Amy Len Kobe - Partner
Amy was previously a Principal at Baird Capital, where she focused on healthcare investments. Her background includes roles at Baxter Healthcare, Healthbox, McKinsey & Company, and Genentech. She earned a BS/MS in chemical engineering from Stanford and an MBA from Kellogg.
Christopher Cox, J.D. - Partner
Christopher is the CEO of Lightswitch Capital and has held significant roles, including Vice Chairman at BrightSphere, which manages over $240 billion in AUM. He has a background as a corporate associate at Weil Gotshal & Manges and holds an AB in politics from Princeton and a JD from NYU.
Shahryar Oveissi - Operating Partner
Shahryar has served as Director at Diomics Corporation and Partner at Rose Capital. He spent eight years as an Operating Partner at Pegasus Capital Advisors, which has $2 billion in AUM.
Christine Neipert, J.D., Ph.D. - IP Advisor
Christine has over 15 years of experience in intellectual property, healthcare reimbursement, and technology commercialization.
Alyse Passaglia - VP HR & Operations
Alyse previously worked at GCM Grosvenor and is responsible for HR and operations at InVivium Capital.
To pitch to InVivium Capital, startups should send an email to info@invivium.com. It is important to include a comprehensive pitch deck that outlines the business model, market opportunity, and the innovation's potential impact on patient care. The firm appreciates detailed presentations that clearly convey the value proposition and the competitive landscape.
Response times may vary, but founders should expect to hear back within a few weeks. Warm introductions are preferred, as they can facilitate a more favorable review of the pitch.
What are InVivium Capital's investment criteria?
InVivium Capital focuses on biotechnology and medical devices, targeting transformative healthcare innovations that can significantly enhance patient care and outcomes. The firm looks for opportunities that create substantial value across the healthcare ecosystem.
How can startups apply or pitch to InVivium Capital?
Startups can reach out to InVivium Capital via email at info@invivium.com. It is advisable to include a detailed pitch deck that outlines the business model, market opportunity, and how the innovation addresses a significant healthcare challenge.
What makes InVivium Capital different from other venture capital firms?
InVivium Capital distinguishes itself through its exclusive focus on transformative healthcare innovations and its ability to provide follow-on capital through strategic partnerships. The firm leverages its extensive network and expertise in healthcare to support the growth of its portfolio companies.
What is the geographic scope of InVivium Capital's investments?
The firm primarily invests in the United States but is open to considering opportunities in global and under-ventured regions, allowing for a broader investment horizon.
What is the typical check size for investments made by InVivium Capital?
While specific check sizes are not publicly disclosed, InVivium Capital is known to write checks across early to mid-stage investments, with the potential for follow-on investments that can significantly exceed initial amounts.
What kind of post-investment involvement does InVivium Capital have?
InVivium Capital actively supports its portfolio companies through strategic partnerships and access to follow-on capital, ensuring that they have the resources needed for growth and development.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.